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The immune response to normal joint proteins probably plays a critical role in
the joint destruction of rheumatoid arthritis (for review, see references 1 and 2) .
Many patients have detectable immunity to various connective tissue components
(3-5), and arthritiscan be induced in rodents by immunizingthem either with col-
lagen or proteoglycans isolatedfrom cartilage (6, 7) . Localizing determinants ofcon-
nective tissue with the capacity to generate immunogenic responses may give us a
better understanding of the way in which arthritis is initiated and regulated .
Ourlaboratory has previously reported (8) that a cyanogen bromide (CB)' pep-
tide of type II collagen (CII) (CB11) carried important epitopes for the induction
of arthritis in mice . We and others (9-11) have also found that injection ofCII but
not type I collagen intravenously would induce resistance to arthritis in rodents.
Oral feedingofnative but not denatured CII prevented arthritis in mice (12) . How-
ever, delineation of determinants important for resistance to arthritis had not yet
been reported .
The present experiments were undertaken to determine if specific regions ofCII
capable ofinducing resistance could be identified . CII exists in vivo as ahomotrimer
with arather rigid helical conformation . We firstdetermined that, under the condi-
tions used, either native or denaturedCII(obtained by thermal denaturation) would
suppress collagen-induced arthritis . We then cleaved CII into smaller fragments,
isolated the resulting peptides, and tested the major ones for suppressive activity.
Finally, we generated synthetic peptides, 21-26 aminoacids in length, corresponding
to selected regions of CB11 and injected them into either adult or neonatal mice
before immunization in order to define a suppressive epitope of CII .
Materials and Methods
Animals.
￿
DBA/1 mice were obtained from TheJackson Laboratory (Bar Harbor, ME),
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maintained in groups of six in polycarbonate cages, and fed standard rodent chow (Ralston
Purina Co., St. Louis, MO) and water ad libitum. The environment was specific pathogen
free, and sentinel mice were tested routinely for mouse hepatitis and Sendai viruses. Neo-
natal mice were obtained by breeding mice from The Jackson Laboratory in our facility.
Mice were immunized at 8-12 wk of age.
Preparation of CII and CB Peptides.
￿
Native CII was solubilized from the sternae of adult
chickens by limited pepsin digestion, as described earlier (13). Purified al(II) chains, obtained
by thermally denaturingthe CII, were subjected to nonenzymatic cleavage with CB and the
resultingpeptides isolated as described by Miller (14). Studies describing the isolation, criteria
of purity, and physiochemical properties of each of the CB peptides have been reported in
detail elsewhere (15).
Chemical Synthesis ofOligopeptides of CBII.
￿
Oligopeptides representing sequences of chick
CII were chemically synthesized by a solid-phase procedure described previously (16) using
a peptide synthesizer (990; Beckman Instruments, Inc., Fullerton, CA). Protected tBoc amino
acids were purchased from Peninsula Laboratories, Inc. (Belmont, CA) and coupled sequen-
tially to a benzhydrylamine resin. Deprotection was achieved with trifluoroacetic acid (25%
in dichloromethane), and coupling was obtained in the presence of dicyclohexyl-carbodiimide.
The completed peptide was cleaved from the resin, and the side chain protecting groups were
removed by treatment with liquid HF at 0°C . The desired peptide was initially purified by
filtration through a Sephadex G-25 column (4.0 x 60 cm) previously equilibrated with 0.1
M acetic acid. The effluent was collected in 10-ml fractions, and aliquots were taken for fluores-
camine analysis. The remaining peptide fraction was pooled, lyophilized, and further purified
by reverse-phase HPLC. Separation was obtained using an HPLC system (Beckman Instru-
ments, Inc.) and an ODS-3 (1 x 25 cm) semipreparative column (Whatman Inc., Clifton,
NJ). Buffer A was 0.05% trifluoroacetic acid and buffer B was 0.05% trifluoroacetic acid
in acetonitrile. The gradient consisted of 20-3017o B in 30 min at 2 .0 ml/min. The elution
was monitored at 230 nm and confirmed by reaction with fluorescamine. Aminoacid compo-
sition of the final peptide was determined with an automatic amino acid analyzer (121 MB;
Beckman Instruments, Inc.), and amino acid sequences were confirmed by automatic Edman
degradation (890 M; Beckman Instruments, Inc.). The amino acid content found was f 10%
theoretical, and amino acid sequence analysis confirmed the peptide structure.
Tolerization.
￿
When native CII was used for tolerization, it was first dissolved at a concen-
tration of 1 mg/ml in 0.1 M acetic acid by stirring overnight at 4°C, then dialyzed against
0.15 M NaCl, 0.02 M sodium phosphate, pH 7.4 (PBS). CB peptides and synthetic peptides
were solubilized directly in PBS at a concentration of 1 mg/ml. In some experiments, CII
was thermally denatured by placing native CII dissolved in PBS in a boiling water bath for
10 min immediately before use. To tolerize adult mice to CII, CB, or synthetic peptides,
each animal was given 1 mg of the antigen intravenously either as one dose or as daily doses
of 0.33 mg each for three consecutive days. In some experiments a larger dose of antigen,
5 mg/mouse, was given as 1 .66 mg daily for three consecutive days. Mice were immunized
3 d after the last intravenous injection. Neonatal mice were tolerized using a protocol de-
scribed by Gammon et al. (17), in which antigen emulsified with IFA was injected in-
traperitoneally. Each mouse received 100 kg of antigen in 0.1 ml of emulsion. The mice were
injected within 24 h of birth. When they were 8 wk of age, they were immunized with CII
and observed for arthritis as described below.
Immunization.
￿
For routine immunization, antigen (normally chick CII) was dissolved in
0.01 N acetic acid and emulsified with an equal volume of CFA. CFA was made by grinding
heat-killed, freeze-dried Mycobacterium tuberculosis (Fisheriesand Food Central Veterinary Lab.,
Weybridge Surrey, UK) with a mortar and pestle and then adding the ground M. tuberculosis
to IFA (Difco Laboratories, Detroit, MI) at a ratio of 4 mg/ml. The antigen solution was
added dropwise to the CFA while continuously mixing with a homogenizer (model 23; Virtis,
Gardner, NY). The temperature was maintained by an ice bath. The resulting emulsion was
injected intradermally into the base of the tail. Each mouse received a total volume of 0.05
ml containing 100 jug of M. tuberculosis and 100 jug of antigen.
Measurement of the Incidence of Arthritis.
￿
The presence of arthritis was determined by ex-
amining and scoring each of the forepaws and hindpaws on a scaleof0-4, as described else-MYERS ET AL.
￿
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where (18). There were two separate examiners, one of whom was unaware of the identity
of the treatment groups. Each mouse was scored three times a week by visual examination
beginning 3 wk post-immunization and continuing through 8 wk post-immunization. In some
experiments, the data were expressed as the percentage ofarthritic limbs per group ofmice,
plotted either at various time points or at 6 wk post-immunization. Analyzing the number
oflimbs involved rather than the number of mice permitted use ofsmaller groups. It assumed
that the occurrenceofarthritis in a limb was random and not related to whether other limbs
in the same mouse were involved. To confirm the validity of this assumption, the incidence
of arthritis (number of animals with one or more arthritic limbs) was also analyzed at one
time point, usually 6 wk post-immunization.
Measurement of SerumAntibody Titers.
￿
Mice were bled at 4 and 8 wk after immunization
to test for antibodies reactive with native CII or CB peptides ofcollagen using a modification
of an ELISA, previously described (19). Briefly, native CII or the antigen to be tested was
dissolved in 0.01 M acetic acid at 4 mg/ml and diluted to a final concentration of 5 Rg/ml
in 0.1 M NaHC03 immediately before use. Microtiter plates (Nunc, Roskilde, Denmark)
were coated by adding 100-pl aliquots of each collagen preparation to the wells, incubating
overnight at VC, and washing the plates to remove unbound collagen. Sera for analysis were
serially diluted with 0.15 M NaCl, 0.05 M Tris-HCI, pH 7.4, containing 0.0570 Tween 20,
and added to the collagen-coated microtiter plates in 100-ill aliquots. After incubation over-
night, the wells were washed and 100 Al ofperoxidase-conjugated goat anti-mouseIgG (Cappel
Laboratories, Cochranville, PA) was added. Plates were incubated for 4 h, washed, and devel-
oped using 40 mg oforthophenylenediamine dissolved in 100 ml of citrate phosphate buffer,
pH 5.5, to which 40 Fd of 30% H202 was added immediately before use. After 15 min, the
absorbanceat 490 nm was measured usingan automated reader (Vmax; Molecular Devices,
Menlo Park, CA). A standard serum was added to each plate in serial dilutions. From these
values, a standard curve was derived by computer analysis using a four-parameter logistic
curve. Results are reported as units of activity, derived by comparison of test sera with the
standard serum, which was arbitrarily defined as having 50 U of activity.
Statistical Analysis.
￿
The incidences of arthritis in various groups of mice were compared
using either the Kruskal Wallis analysis of variance or X2 analysis with Yates' correction. An-
tibody levels were compared using the student's t test.
Results
Suppression ofArthritis with Intact CII.
￿
Mice injected intravenously with native or
denatured CH before immunization were resistant to arthritis. By 6 wk post-
immunization, the control groups, given OVA or type I collagen, had an arthritis
incidence of 17/18 (94%) or 5/5 (100%), respectively; animals given denatured CII
had an incidence of 1/18 (6%); and animals given native CII had no arthritis (Table
I). The incidence ofarthritis in groups receiving either native or denatured CII were
both significantly different from OVA controls, with p <0.004 by Kruskal Wallis anal-
ysis of variance. Mice were also evaluated according to the mean percentage of ar-
thritic limbs per group ofsix mice (Table I). By 6 wk post-immunization, the control
group injected with OVA had 56% arthritic limbs and the group given type I col-
lagen had 46% arthritic limbs. Animals injected with denatured CII had 3% ar-
thritic limbs and animals injected with CH had no arthritis. Both groups administered
CH were significantly different from OVA controls using X2 with Yates' analysis (p
<0.0001).
All of the animals were bled at 4 and 8 wk post-immunization and tested for anti-
body response to native CII by ELISA. Animals given a tolerizing injection ofeither
native or denatured CII before immunization had significantly lower antibody levels
to CII at both 4 and 8 wk post-immunization, in comparison with control mice in-2002
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TABLE I
Suppression ofArthritis with Soluble Collagen
Female DBA/l mice, 8 wk of age, were tolerized by intravenous injection of
1 mg of OVA, denatured CII, native CII, or type I collagen, 3 d before im-
munization with 100 ug of native CII. Data is expressed as the number of
mice with arthritis and the number ofarthritic limbs at 6 wk post-immunization.
The data were analyzed statistically using Kruskal Wallis analysis ofvariance
and student's t test. Mice were bled 4 wk post-immunization and tested for
antibody to CII using ELISA. Each serum was diluted 1:73,000, and values
are expressed as mean units of activity. Statistical analysis compared the ex-
perimental (CII-injected animals) with control (OVA-injected animals).
' p < 0.004 using Kruskal Wallis analysis of variance.
t p < 0.0001 using student's t test.
S p < 0.005 using student's t test.
jected with OVA (Table I). Animals given denatured CII had antibody levels inter-
mediate to those given native CII and controls that correlated well with the inci-
dence of disease.
The onset of arthritis was also delayed in animals given denatured CII (Fig. 1).
Control animals given OVA had the onset of arthritis beginning day 21, followed
by a rapid increase in the number of arthritic limbs. A plateau occurred N6 wk after
immunization, but the animals continued to develop newly affected limbs until the
termination of the study at 8 wk post-immunization. Animals given native CII be-
fore immunization had no arthritis develop throughout this study, but animals given
denatured CII had the onset ofdisease beginning around day 35 post-immunization.
The suppressive effect began to fade by 8 wk after immunization, as evidenced by
an increasing frequency of arthritis and by smaller differences in antibody levels.
Days Post-Immunization
FIGURE 1. Suppression of arthritis
with intact CII. Female DBA/1 mice,
8 wk ofage, were tolerized by intrave-
nous injection of 1 mg ova (0), dena-
tured CII (*), or native CII (/) 3 d
before immunization with 100 ug of
native CII. There were six mice in each
group. Arthritis was first evident at day
20, and mice were evaluated three
times weekly for the presence of ar-
thritis. Data are expressed as the per-
centage of limbs that were arthritic.
Antigen
injected
Arthritic
mice
Arthritic
limbs
Mean antibody
levels to CII
4 wk post-immunization
OVA 17/18(94%) 40/72 (56%) 60.5 t 26
CII (denatured) 1/18 (6%)' 2/72 (39')t 14.0 t 16S
CII (native) 0/18(0%)- 0/72 (0%)t 5.3 t 2S
Collagen type I 5/5 (100%) 11/24(46%) 58.4 t 28MYERS ET AL.
￿
2003
Suppression ofArthritis with Fragments ofCII.
￿
To localize regions ofthe molecule
responsible forinducing tolerance, CII was cleaved by treatment with CB, and the
resultingpeptides were individuallyisolated. CB peptides 11, 10, and 8 were selected
forfurtherexperimentation because they comprise 75% ofthe entire molecule and
because our earlier work (8) showed that sera from arthritic animals immunized
with CII contain antibodies that recognize these peptides selectively. We injected
mice with the peptides 11, 10, or 8 intravenously and challenged them 3 d later by
immunization with intact CII. By 6 wk post-immunization, 92% of the animals
given OVA, 69% ofthe animals given CB10, and 83% ofthe mice given CB8 were
arthritic (Table II). In contrast, only 25% of the mice given CB11 were arthritic
(p <0.002). Both native CII and CB11 effectively suppressed the overall antibody
responses to intact CII and to each ofthe CB peptides tested, while neither CB8
nor CB10 did so (Table III).
Suppression ofArthritis in Adult Mice with a Synthetic Peptide Representing Sequences of
Chick a1(II)CB11. To further localize the most important determinant ofsuppres-
sion, five synthetic peptides, each 21-26amino acidsinlength, were generated. These
peptides corresponded to sequences ofCB11 selected by comparison ofCII to type
I collagen and identifying areas with the greatest differences. CII and type I col-
lagenare 70% homologous within the CB11 region, excluding glycine at everythird
residue. The greatest differences are confined to two areas, the first 126-140 amino
acids from the NH2 terminal, and the second 240-257 from the amino terminal
ofal(II)CB11. (20). Ofthe five peptides tested, only CB11 122-147 had suppressive
activity (Table IV). Mice receiving CB11 122-147 had an incidence of 9/18 (50%)
arthritis and 16/72 (22%) arthriticlimbs, whencompared with animals given OVA,
which had 17/18 (94%) arthritic mice and 39/72 (54%) arthritic limbs (p = 0.05
and p = 0.01, respectively). Alarger dose (5 mg/mouse) ofCBll 122-147 was even
more suppressive, giving 2/6 (33%) arthritic mice and 4/24 (17%) arthritic limbs,
TABLE 11
Suppression of Arthritis with Collagen Fragments
Female DBA/1 mice, 8 wk ofage, were randomly allocated into groups offrom
6 to 16 mice, and each group was injected intravenously with 250,ug ofOVA,
CII, CB8, CB10, or CBI 1 daily for 3 d. 3 d after the last injection, they were
immunized with 100 t+g ofCII. Data are expressed as the number ofarthritic
mice and the number ofarthritic limbs per groupat 6 wk post-immunization.
The number ofarthritic animals given CB11 and CII was significantly differ-
ent from controls given OVA.
" p < 0.002 using Kruskal Wallis analysis of variance.
1 p 4 0.0001 (X2 = 19.3 for mice injected with native CII; X2 = 20.7 for mice
injected with CB11 ; both had Yates' correction applied).
S p 4 0.03 (X2 with Yates correction = 4.5).
Antigen
injected
Arthritic
mice
Arthritic
limbs
OVA 11/12(92%) 27/48(56%)
C11 0/12(0%)' 0/48(0%)l
CB8 5/6 (83%) 10/24(42%)
CB10 11/16(69%) 22/64 (34%)S
CB11 3/12 (25%)' 5/48 (10%)I2004
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TABLE III
Suppression of Antibodies to Collagen Using Collagen Fragments
k
￿
Atign
￿
Mean antibody titers to collagen fragments n
wpost-immunization injected
4
￿
OVA
CII
CB8
CB10
CB11
8
￿
OVA
CII
CB8
￿
57 ± 6
￿
14±4
￿
10±5
￿
30±8
CB10
￿
61 t 9
￿
18± 11
￿
13±8
￿
35± 16
CB11 32±51 3±2S 3±2s 6±2*
DBA/1 female mice, 8 wk of age, were injected intravenously with 250 /A.g of either OVA,
CII, CB8, CB10, or CB11 daily for 3 d. 3 d after the last injection, they were immunized
with 100 ftg ofnative CII. Antibody levels to CII and CB peptides 8, 10, and 11 were deter-
mined by ELISA at 4 and 8 wk post-immunization. Results are expressed as mean units
of activity ± SD. Each result is compared with the result obtained in the mice injected with
OVA using student's t test .
* p 4 0.005 .
t p 4 0.01 .
S p 4 0.05.
p = 0.009 andp = 0.003, respectively. Of note is that CB11 116-137 overlaps CB11
122-147, suggesting the region from 137 to 147 is critical.
Suppression ofArthritis by Neonatal Injection ofaSynthetic Peptideof CII .
￿
Because neo-
natal tolerance maybe due to adifferentmechanism than adult tolerance, we deter-
mined which epitopes of CH were important in suppressing arthritis when the an-
tigens were givenneonatally. Using aprotocol forinducing neonatal tolerancedescribed
in Materials and Methods, CB11 and three of its synthetic peptides were injected
TABLE IV
Suppression ofArthritis in Adult Mice with Synthetic Peptides of CB11
Female DBA/1 mice, 8 wk ofage, were randomly allocated into groups of6-18
mice and injected intravenously with 0.33 mg of OVA, CII, or one of the syn-
thetic peptides daily for 3 d. 3 d after the last injection, they were immunized
with 100 ug of CII . Data are expressed as the number of arthritic mice and
the number of arthritic limbs per group at 6 wk post-immunization. Results
were analyzed by X2 with Yates' correction.
` p 4 0.01 .
1 p < 0.05 .
Antigen injected
Mice with
arthritis
Limbs with
arthritis
OVA 17/18 (947 .) 39/72 (54%)
Chick CB11 3/12 (25%)* 5/48 (10%)*
Synthetic CB11 122-147 9/18 (50%)1 16/72 (22%)'
Synthetic CB11 239-263 6/6 (100%) 12/24 (50%)
Synthetic CB11 116-137 12/12 (100%) 23/48 (48%)
Synthetic CB11 97-122 6/6 (100%) 13/24 (54%)
Synthetic CB11 148-173 6/6 (100%) 10/24 (42%)
CII CB8 CB10 CB11
60t 12 1318 5±4 40± 15
5±2* 1 ±0.71 1 ±0.61 3±31
58±5 17±7 13±6 31 ± 15
61 ± 10 4±3 4±2 43± 17
28± 71 2± 1t 2±0.4 6±21
55± 13 18± 13 18± 12 37± 11
5±4* 1 ± 1t 1 ±0.41 3±2*MYERS ET AL.
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TABLE V
Suppression of Arthritis in Neonatal Mice with Synthetic Peptides of CB11
Neonatal DBA/l mice were injected intraperitoneally with 0.1 mg of CBI 1
or one of three synthetic peptides emulsified with IFA. At 8 wk of age, mice
were immunized with 100 t~g of CH. Data are expressed as the number of
arthritic mice and the number of arthritic limbs per group at 6 wk post-
immunization. Results were analyzed by X2 with Yates' correction for non-
parametric data and by student's t test for antibody levels.
p 4 0.02.
$ p 4 0.001 .
into neonatal mice that were subsequently immunizedwith CII at 8wkofage. Both
CB11 andthe syntheticpeptide CB11 122-147 were suppressive. None ofthe six mice
given CB11 neonatally developed arthritis and 2/7 (29%) of the mice given CB11
122-147 developed arthritis, compared with 83% of mice given CB11 239-263 or
CB11 116-137 (Table V). The structureofthe synthetic peptideCB11 122-147 is shown
in Fig. 2.
Discussion
In this study, we have identified an epitope of CII that is ofcritical importance
for regulation of arthritis. It has long been felt that autoimmunity to CII plays a
major role inthepathogenesis ofcollagen-induced arthritisand rheumatoid arthritis
as well (1-7). Therefore, identification of critical determinants of CII that trigger
immune responsescanleadto better understandingofthemechanisms behind their
immunopathogenicity.
Our laboratory has previously shown (8) that the CB11 contained critical deter-
minants forinduction ofdiseaseinmice. In addition, otherinvestigators have shown
that intravenous administration of soluble CII (10), collagen-coupled spleen cells
(9), and partiallypurifiedcollagenous peptides (11)are capableofsuppressingcollagen-
inducedarthritis in rats. Yet localization ofcritical determinants for the suppressive
phenomenon remained to be determined. We have confirmed that resistance to
collagen-induced arthritis could also be induced in DBA/1 mice by intravenous in-
jection ofCII. This resistance was associated with tolerance to the immunizing an-
tigen as measured by decreased antibody levels. Furthermore, although tolerance
FIGURE 2.
￿
Structure ofa syn-
137
￿
thetic peptide that confers pro-
I
￿
tection against arthritis. The
P-T-G-P-L-G-P-R-G-Q-T-G-&-L-G-Z-A-G-P-tt-G-S-Q-G-P-R
￿
synthetic oligopeptide of CB11
was chemically synthesized by
CB11
￿
122-1s7
￿
a solid-phase procedure as descri-
bed in Materials and Methods.
Antigen injected
Mice with
arthritis
Limbs with
arthritis
Mean antibody
levels to CII
No antigen 5/6 (837 .) 12/24 (50%) 60.5 t 22.8
Chick CBI 1 0/6(0%)' 0/24 (0%)t 6 t 0.6t
Synthetic CBll 122-147 2/7 (29%) 2/28 (7%)' 18.5 t 7.8t
Synthetic CBll 239-263 5/6 (83%) 12/24 (50%) 58.7 t 10.5
Synthetic CBll 116-137 5/6 (83%) 13/24 (54%) 79.5 t 38.52006
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induced by native collagen was profound, the phenomenon was not dependent upon
native antigen. Both denatured collagen and peptide fragments derived by CB digestion
were effective, although slightly less potent. The finding that denatured collagen frag-
ments were effective is similar to that of Englert et al. (11), who found that partially
purified CB peptides enriched for CB10-induced resistance in rats. However, in the
DBA/1 mouse, the most potent and consistently suppressive fragment was CB11.
CB10 showed a trend toward suppressing arthritis but this was not significant with
the number of mice tested. It is possible that inclusion of additional animals might
have identified another, perhaps less potent, tolerogenic site on CB10. It may also
be that species differences exist in the recognition of tolerogenic peptides.
Ofparticular importance, however, was the finding that a 26-amino acid synthetic
peptide correlating with CB11 122-147 was capable ofsuppressing arthritis, whether
given to adult animals or neonates. Additionally, because an overlapping peptide
CB11 116-137 did not suppress arthritis, the critical determinant resides within the
region CB11 137-147, an 11-amino acid stretch.
Distinct immunosuppressive epitopes have been demonstrated with several non-
collagenous protein antigens. Hen egg-white lysozyme (21, 22), insulin (23), a ga-
lactosidase (24), and BSA (25) have all been shownto have nonoverlapping immuno-
genic and suppressive epitopes on the same molecule. Studies done in experimental
allergic encephalomyelitis, an animal model for an autoimmune demyelinating dis-
ease, have revealed that the same epitope on myelin basic protein carries the ability
to either suppress or cause disease (26), and an additional inhibitory determinant
could be found, distant from the encephalitogenic site (27). In addition, a synthetic
peptide composed of the NH2-terminal nine amino acids of myelin basic protein,
when given neonatally, rendered mice resistant to subsequent disease induced by
immunization with the same peptide, although such treatment did not make them
resistant to disease induced by immunization with the whole rat myelin basic pro-
tein (28).
The superiority of a particular peptide over others of similar size in initiating im-
mune responses is not completely understood. Recent studies of Grey, Gefter, and
Unanue, and their coworkers (29-31), have suggested that the immunodominant
peptide may bind with greater affinity to the MHC antigen on the APC than do
other peptides that have no effect on the immune response. Alternately, investigators
have proposed that certain protein determinants trigger a greater diversity of T cells
to respond with a wider range of fine specificities than other determinants can in-
duce (32). These two hypothetical mechanisms may both be playing a role in the
case of the immune response to collagen.
In addition, mechanisms have been proposed to explain the phenomenon that
intravenous injection of a protein can lead to profound suppression of the subse-
quent immune response to that antigen. Suppression may be the property of a par-
ticular cell, or an intrinsic property of the immune system, or carried out by known
components that become suppressive only under particularcircumstances (33). Pos-
sibly, priorexposure to exogenous peptide causes inactivation or deletion of certain
T cell clones, as has been proposed in neonatal tolerance to cytochrome and lyso-
zyme peptides (28, 34). The induction of T cells capable of suppressing Th cells,
either by secretion of lymphokines or via cytotoxicity, has also been proposed (33).Inaddition, the display ofantigen on inappropriateAPC may result in the inactiva-
tion, rather than the activation, ofspecific T cells(35). The suppression ofcollagen-
induced arthritis with intravenous injection ofCII has been reported to be antigen
specific and transferrablewith cellsto naiveanimals(36-38). Recent studies showed
abrogation ofsuppressionofCIA bycyclophosphamide treatment(39) and suppres-
sion ofCIA by a T cell hybridoma (40). This suggested that T cells mediated the
suppression ofCIA. We have found that CD4+ cells play a role in the suppressive
phenomenon induced by intravenous injection of CII (41), but a role for each of
the other mechanisms that have been proposed cannot be ruled out.
We have successfully suppressed arthritis by peptide-induced tolerization. Fur-
therstudies arecurrentlyunderway todeterminewhich amino acidsofCBll 122-147
are pivotal for its immunological activities in the DBA/l mouse. Abetter definition
ofdeterminants critical for regulation of arthritis may lead to improved therapies
exploiting the observation that tolerance to certain immunogenic epitopes ofau-
toimmune proteins can result in a downregulation ofthe immuneresponse andulti-
mately of the autoimmune disease.
Summary
We have previously reported that collagen-induced arthritis can be suppressed
by intravenous injection of native type II (CII) but not type I collagen. We have
now identified denatured fragments ofCII capable ofsuppressingcollagen-induced
arthritis and inducing tolerance. Purified CII was cleaved with cyanogen bromide
(CB), and the major resulting peptides were isolated. Female DBA/1 mice were ad-
ministered OVA, native CII, orone ofthe CB peptides, intravenously, before immu-
nization with native CII. 6 wkafter immunization, mice tolerized with CII or CBll
had a markedly lower incidence of arthritis compared with controls. There was a
correlation between the overall antibody response and the incidence ofarthritis. In
addition, animals tolerized with either CII or CB11 had a decreased antibody re-
sponse not only to CII, but also to each ofthe other CB peptides tested. To identify
theepitope involved in suppression ofarthritis, five synthetic peptides, 21-26 amino
acids in length, corresponding to selected regions ofCB11, were generated. Each
ofthe peptides was injectedintravenously intomicebefore immunization. Only one
ofthese, CB11 122-147, was capable ofsuppressing arthritis. In addition, micegiven
the synthetic peptide CB11 122-147 neonatally were suppressed forarthritis and an-
tibody responsiveness when immunized with CII at 8 wk of age. Thus, we have
identified CB11 122-147 as an epitope of CII important in induction of tolerance
and suppression ofdisease. Further experiments narrowingdownthepivotal amino
acids forthe immunogenicity ofthis epitope andtherole this epitope plays in induc-
tion and regulation ofdisease will enhance our understanding ofhow the immune
response to collagen affects autoimmune arthritis.
We thank LindaSandell forproviding thesequence ofchickal(H)CB11, andMaanJoudeh,
Gay Spears, andJames Henry for their excellent technical assistance, as well as to Karen
Willard for preparation of this manuscript.
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